Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Biotechnology EquipmentGene Therapeutics & RNAi

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1577522

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1577522

Tissue Microarrays

PUBLISHED:
PAGES: 180 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5600
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16800

Add to Cart

Description

Table of Contents

Global Tissue Microarrays Market to Reach US$14.1 Billion by 2030

The global market for Tissue Microarrays estimated at US$9.1 Billion in the year 2023, is expected to reach US$14.1 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2023-2030. Immunohistochemistry Procedure, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$6.5 Billion by the end of the analysis period. Growth in the Fluorescence In-Situ Hybridization (FISH) Procedure segment is estimated at 6.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.4 Billion While China is Forecast to Grow at 6.3% CAGR

The Tissue Microarrays market in the U.S. is estimated at US$2.4 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.3 Billion by the year 2030 trailing a CAGR of 6.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.1% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR.

Global Tissue Microarrays Market – Key Trends & Drivers Summarized

What Are Tissue Microarrays and How Do They Advance Biomedical Research?

Tissue microarrays (TMAs) are a powerful research tool used to analyze multiple tissue samples simultaneously on a single slide. This technique allows for the efficient examination of a wide variety of tissues, typically sourced from patients or experimental models, making it easier to compare pathological differences, gene expressions, or protein activity across different cases. TMAs have revolutionized biomedical research, particularly in oncology, by enabling the large-scale analysis of tissue samples, which helps identify potential biomarkers, validate diagnostic tests, and assess the efficacy of targeted therapies. Each microarray contains hundreds of tiny, representative cores from different tissue samples, allowing researchers to run experiments like immunohistochemistry (IHC) or in situ hybridization (ISH) on multiple samples at once, significantly saving time and resources compared to traditional methods.

How Are Technological Innovations Shaping the Tissue Microarrays Market?

Technological advancements are driving significant improvements in the functionality and accuracy of tissue microarrays. The introduction of automated TMA construction tools has enabled more precise and reproducible array creation, reducing the variability between tissue cores and ensuring better experimental reliability. Additionally, advancements in digital pathology and imaging technologies have made it possible to analyze TMAs more effectively. High-resolution scanning systems and AI-based image analysis tools allow researchers to quantify and assess tissue markers more quickly and with greater accuracy. Furthermore, innovations in multiplexed immunohistochemistry and the ability to simultaneously detect multiple proteins or genetic markers within a single tissue core are further expanding the utility of tissue microarrays in complex research settings like cancer biology, where multifactorial data is crucial.

What Industry and Healthcare Trends Are Influencing Tissue Microarrays?

In the healthcare and pharmaceutical industries, tissue microarrays are gaining traction due to their critical role in translational research and personalized medicine. With the growing emphasis on developing precision therapies, especially in oncology, TMAs offer an effective platform for identifying specific biomarkers that can guide treatment decisions. In pharmaceutical drug discovery, TMAs are used to evaluate how different drugs impact various tissue types, enabling quicker screening and more informed decision-making in the development of new therapies. Additionally, the increasing demand for more robust and reliable diagnostic tools has encouraged the use of TMAs in validating diagnostic tests for various diseases. In academia and research institutions, the growing trend toward large-scale, data-driven research has positioned tissue microarrays as a valuable tool for conducting high-throughput analyses in studies related to cancer, cardiovascular diseases, and neurodegenerative conditions.

What Factors Are Driving Growth in the Tissue Microarrays Market?

The growth in the tissue microarrays market is driven by several factors. Technological advancements in automated array construction and digital pathology are making TMAs more accessible and efficient, thereby increasing their adoption in research and clinical settings. The rising demand for personalized medicine, particularly in oncology, is significantly boosting the use of TMAs for biomarker discovery and targeted therapy validation. Pharmaceutical companies are increasingly utilizing TMAs to streamline drug development processes, reducing the time and costs associated with evaluating potential treatments. Additionally, the growing focus on developing robust diagnostics for chronic and complex diseases is propelling the need for TMAs in test validation and comparative pathology studies. The expansion of tissue banks and biorepositories, which provide high-quality tissue samples for research, is further supporting the growth of the TMA market. Lastly, increased government funding for cancer research and large-scale biomedical studies is driving the adoption of TMAs in academic and research institutions around the world.

Select Competitors (Total 42 Featured) -

  • 3DHISTECH Ltd.
  • Array Science, LLC
  • Bio Sb
  • Cureline, Inc.
  • Indica Labs, Inc.
  • Innopsys France
  • Mopec, Inc.
  • Novus Biologicals LLC
  • OracleBio
  • OriGene Technologies, Inc.
Show more
Product Code: MCP24412

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Tissue Microarrays - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for High-Throughput Tissue Analysis Propels Growth in the Tissue Microarrays Market
    • Increasing Use of Tissue Microarrays in Cancer Research Expands Addressable Market for Diagnostic and Therapeutic Applications
    • Advancements in Immunohistochemistry (IHC) and In Situ Hybridization (ISH) Technologies Strengthen Business Case for Tissue Microarrays
    • Growing Need for Efficient Biomarker Validation in Personalized Medicine Drives Adoption of Tissue Microarrays
    • Technological Innovations in Multiplexing Techniques Accelerate the Use of Tissue Microarrays in Research and Diagnostics
    • Increasing Focus on Precision Oncology Generates Opportunities for Tissue Microarrays in Tumor Analysis
    • Rising Investment in Translational Research Expands the Market for Tissue Microarrays in Clinical Trials
    • Increasing Prevalence of Chronic Diseases and Cancer Fuels Demand for Tissue Microarrays in Pathology
    • Growing Applications of Tissue Microarrays in Drug Development Strengthens Market for Pharmaceutical Research
    • Expansion of Tissue Banks and Biorepositories Supports Growth of the Tissue Microarrays Market
    • Rising Use of Tissue Microarrays in Immunotherapy Research and Development Expands Market Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Tissue Microarrays Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Tissue Microarrays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Tissue Microarrays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Tissue Microarrays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Immunohistochemistry Procedure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Immunohistochemistry Procedure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Immunohistochemistry Procedure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Fluorescence In-Situ Hybridization (FISH) Procedure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Fluorescence In-Situ Hybridization (FISH) Procedure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Fluorescence In-Situ Hybridization (FISH) Procedure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for In Situ Hybridization Procedure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for In Situ Hybridization Procedure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for In Situ Hybridization Procedure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Procedures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Procedures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Procedures by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Research Organizations End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Tissue Microarrays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Tissue Microarrays by Procedure - Percentage Breakdown of Value Sales for Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures for the Years 2014, 2024 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Tissue Microarrays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Tissue Microarrays by Procedure - Percentage Breakdown of Value Sales for Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures for the Years 2014, 2024 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Tissue Microarrays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • JAPAN
    • Tissue Microarrays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Tissue Microarrays by Procedure - Percentage Breakdown of Value Sales for Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures for the Years 2014, 2024 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Tissue Microarrays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • CHINA
    • Tissue Microarrays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Tissue Microarrays by Procedure - Percentage Breakdown of Value Sales for Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures for the Years 2014, 2024 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Tissue Microarrays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • EUROPE
    • Tissue Microarrays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Tissue Microarrays by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Tissue Microarrays by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Tissue Microarrays by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Tissue Microarrays by Procedure - Percentage Breakdown of Value Sales for Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures for the Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Tissue Microarrays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • FRANCE
    • Tissue Microarrays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Tissue Microarrays by Procedure - Percentage Breakdown of Value Sales for Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures for the Years 2014, 2024 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Tissue Microarrays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • GERMANY
    • Tissue Microarrays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Tissue Microarrays by Procedure - Percentage Breakdown of Value Sales for Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures for the Years 2014, 2024 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Tissue Microarrays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Tissue Microarrays by Procedure - Percentage Breakdown of Value Sales for Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures for the Years 2014, 2024 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Tissue Microarrays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Tissue Microarrays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Tissue Microarrays by Procedure - Percentage Breakdown of Value Sales for Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures for the Years 2014, 2024 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Tissue Microarrays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Rest of Europe Historic Review for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Rest of Europe 16-Year Perspective for Tissue Microarrays by Procedure - Percentage Breakdown of Value Sales for Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures for the Years 2014, 2024 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Tissue Microarrays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Tissue Microarrays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Asia-Pacific Historic Review for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Asia-Pacific 16-Year Perspective for Tissue Microarrays by Procedure - Percentage Breakdown of Value Sales for Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures for the Years 2014, 2024 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Tissue Microarrays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of World Historic Review for Tissue Microarrays by Procedure - Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of World 16-Year Perspective for Tissue Microarrays by Procedure - Percentage Breakdown of Value Sales for Immunohistochemistry Procedure, Fluorescence In-Situ Hybridization (FISH) Procedure, In Situ Hybridization Procedure and Other Procedures for the Years 2014, 2024 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of World Historic Review for Tissue Microarrays by End-Use - Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of World 16-Year Perspective for Tissue Microarrays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Research Organizations End-Use and Other End-Uses for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!